Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
About the Neuroscience Forum FORUM MEMBERSHIP The IOM in 2006 established the Forum on Neuroscience and Nervous (AS OF DECEMBER 2009) System Disorders. The Forum is designed to provide its members with a venue for exchanging information, sharing individual views, and allowing a structured opportunity for dialogue and discussion while scrutinizing critical Alan Leshner (Chair) Husseini Manji and possibly contentious scientific and policy issues. Representatives from American Association for the Advancement Johnson & Johnson Pharmaceuticals government, industry, academia, patient advocacy organizations, and other interested parties serve as Forum members. It convenes three times a year to of Science Eve Marder 2009 ANNUAL REPORT Huda Akil Brandeis University confer on subject areas of mutual interest and concern. At its meetings, the University of Michigan, Ann Arbor Forum identifies and discusses emerging scientific and policy issues related to Jonathan Moreno basic neuroscience and nervous system disorders, as well as effective clinical Marc Barlow University of Pennsylvania interventions and policy options. The Forum also sponsors workshops (sympo- GE Healthcare Steve Hyman welcomes participants to the workshop on Mental, Neurological, and Substance Use Disorders in sub-Saharan Africa, August 2009 Michael Oberdorfer sia) as an additional mechanism for informing the membership of the Forum, Mark Bear National Eye Institute, NIH Neuroscience other relevant stakeholders, and the public. Information about past or upcom- Massachusetts Institute of Technology Blueprint representative ing meetings is available at the Forumâs website, www.iom.edu/neuroforum. Daniel Burch Kathie Olsen FORUM SPONSORSHIP About the Institute of Medicine The Institute of Medicine serves as adviser to the nation to improve health. CeNeRx Biopharma Dennis Choi National Science Foundation Atul Pande Financial support for the Forum is derived from federal agencies, patient advocacy organizations, industry, and a non-profit membership society. FORUM ON Established in 1970 under the charter of the National Academy of Sciences, Emory University GlaxoSmithKline the Institute of Medicine provides independent, objective, evidence-based Alzheimerâs Association National Institute on Alcohol Abuse and advice to policymakers, health professionals, the private sector, and the pub- lic. The mission of the Institute of Medicine embraces the health of people Timothy Coetzee FastForward of the National Multiple Sclerosis Society Menelas Pangalos Wyeth Research AstraZeneca Pharmaceuticals CeNeRx Biopharma Alcoholism National Institute on Drug Abuse NEUROSCIENCE everywhere. Steven Paul Eli Lilly and Company National Institutes of Health Neuroscience David Cohen Eli Lilly and Company GE Healthcare Blueprint IOM Staff Columbia University, Society for Neuroscience representative William Potter GlaxoSmithKline Johnson & Johnson Pharmaceuticals National Institute of Mental Health National Institute of Neurological Disorders AND Merck Research Laboratories Bruce Altevogt, Ph.D. Lundbeck Research USA, Inc. and Stroke Richard Frank Project Director Paul Sieving NERVOUS SYSTEM Merck Research Laboratories National Multiple Sclerosis Society GE Healthcare Sarah Hanson National Eye Institute The Michael J. Fox Foundation for National Science Foundation Associate Program Officer John Griffin Parkinsonâs Research Society for Neuroscience Rae Silver Johns Hopkins University National Eye Institute Wyeth Research Lora Taylor Columbia University DISORDERS Senior Project Assistant Richard Hodes National Institute on Aging William Thies National Institute on Aging IOM Board on Health Sciences Policy Alzheimerâs Association Katie Hood Neuroscience Forum Funding: 2009 Andrew M. Pope, Ph.D. Nora Volkow Director The Michael J. Fox Foundation for National Institute on Drug Abuse Nonprofit Industry Federal Parkinsonâs Research Kenneth Warren Steven Hyman National Institute on Alcohol Abuse and 19% Harvard University Alcoholism Thomas Insel Frank Yocca National Institute of Mental Health AstraZeneca Pharmaceuticals 38% BOARD ON Story Landis Stevin Zorn HEALTH National Institute of Neurological Disorders Lundbeck Research USA, Inc. SCIENCES and Stroke For additional information on the Forum on Neuroscience and Nervous System Charles Zorumski 43% POLICY Disorders visit the Forumâs website at www.iom.edu/neuroforum, Washington University, St. Louis or call Bruce Altevogt at (202) 334-3984.
MESSAGE REFLECTING BACK LO O K I N G A H E A D FROM THE CHAIR FORUM ACTIVITIES IN 2009 FORUM ACTIVITIES FOR 2010 Mental, Neurological, and Substance Use Disorders in sub-Saharan Africa Sex Differences and Implications for Translational Neuroscience Research T he Institute of Medicine (IOM) established the In August, the Forum, in collaboration with the Forum on Health and Nutrition of the Uganda National The Forum is hosting a workshop to explore the key principles and strategies used by basic transla- Forum on Neuroscience Academy of Sciences, convened an international workshop in Kampala, Uganda on quality of care tional researchers and industry in studying sex differences in the neurosciences for the therapy devel- and Nervous System issues for mental, neurological, and substance use disorders in sub-Saharan Africa. In light of the opment pathway. Speakers will outline the public health importance of studying sex difference in the Disorders to engage neu- economic limitation of most sub-Saharan African countries, the workshop set out to explore areas nervous system, in health and sickness, including the potential application to healthcare delivery. A CNS Clinical Trials: Suicidality and Data Collection workshop participants, June 2009 roscience leaders from private sector where policies might improve care, opportunities that could be used to better ensure continuity of care large emphasis will be on discussing the scientific principles that should be considered when design- sponsors of biomedical and clinical and sustainability within a countryâs health care system, and resources that are presently available or ing pre-clinical experiments that will examine sex differences, including strategies to bridge between research, federal agencies sponsor- could be made available to aid in implementation of treatments and prevention projects. Participants pre-clinical and clinical studies; when and how sex differences should and should not be considered; ing and regulating basic biomedical emphasized the need for more action, investment, and commitment by all stakeholders, national and and the key principles and strategies used by academic clinicians to effectively utilize basic research WORKING GROUPS and clinical research, private founda- international. The summary of the workshop will be released in Spring 2010 and will be found on the for pre-clinical and clinical application and study. tions, the academic community, and Working groups are established and maintained by interested members and are open to all member- Forumâs website (www.iom.edu/neuroforum). other consumers. Facilitating Translational Research for Clinical Neuroscience Applications ship. The Forumâs working groups engage in regular discussions, usually via teleconferences, on topics 2009 SfN Annual Meeting: Social Issues Roundtable Individuals from pharmaceutical and diagnostic industry, academia, and the National Institutes of of interest to that group. Workshop topics often originate from working groups and are organized by an Through its quarterly meetings and Alan Leshner The Forum organized the Social Issues Roundtable at the 2009 meeting of the Society for Neuroscience. Health will join members of the Forum in a meeting on translational research for clinical neuroscience independently appointed workshop planning committee. public workshops, the Forum has provided a venue where its members, The purpose of this discussion was to begin to engage neuroscientists in a dialogue about the ethical applications. The meeting will stimulate discussions aimed at improving the understanding between other leaders from the neurosciences, and members of the public can have Translational Neuroscience candid discussions about issues of mutual interest. We believe these discus- and social implications of research findings as the field continues to find the scientific underpinnings what pharmaceutical and diagnostic developers are looking for and how academic researchers can best The translational neuroscience working group was established to focus on identifying areas of synergy sions enhance understanding of research and clinical issues associated with of what âmakesâ us human. For example, new insights into the nature of the brain and mind can have contribute to the partnership in a meaningful way in order to improve the neuroscience translational where public and private sector stakeholders can partner to improve the efficiency and effectiveness of the nervous system among the scientific community and the general public, great implications for such concepts as the self, soul, free will, or what it means to be human. Speakers research pipeline. Discussions and presentations will also focus on how to bridge the interface between drug discovery and development for neurological and mental disorders. The group is currently develop- and provide a mechanism to foster partnerships among stakeholders. This was in the roundtable discussed both the nature of those issues, and ways the scientific community can best basic and drug/diagnostic development researchers in the neurosciences. ing a workshop aimed at improving the understanding between what pharmaceutical and diagnostic exemplified in 2009 when the Forum collaborated with the Uganda National engage the public, find common ground, and minimize the tension that could arise between the field Glutamate-related Biomarkers for Disorders of the Nervous System developers are looking for and how academic researchers can best contribute to the partnership in a Academy of Sciences to host an international workshop on mental, neurologi- and the rest of society. Identification of reliable biomarkers reflecting glutamatergic dysfunction may permit selection of meaningful way in order to improve the neuroscience translational research pipeline. cal, and substance use disorders. The workshop, a true collaboration across CNS Clinical Trials: Suicidality and Data Collection patients who will gain greater benefit from glutamate-directed treatments. Present medications, while continents, brought together a wide range of stakeholders to discuss important Social Issues in Neuroscience The Forum hosted a workshop in June in response to an emerging need to examine a recent Food and advanced over the initial compounds, nevertheless provide unsatisfactory treatment for individuals topics that we hope will move to the fore issues related to these disorders that A working group was established to engage neuroscientists in a dialogue about the critical time neuro- Drug Administration policy that requires all clinical protocols for products developed in the Division of with a range of central nervous system disorders with persistent negative symptoms, significant cogni- plague so many individuals in this region. science is entering with regard to ethical and social implications of research findings as the field con- Psychiatry Products of the FDA, whatever the indication, to include a prospective assessment for suicid- tive deficits, and poor function, characteristics associated with glutamatergic dysfunction by emerging The Forum undertook a broad set of initiatives in 2009 and, in 2010, the tinues to find the scientific underpinnings of what âmakesâ us human. The group is continuing efforts ality. Workshop participants examined and discussed the state of currently available data, data analysis evidence. The goal of the workshop is to gain an enhanced understanding of the role of biomarkers, as Forum plans to host a variety of activities, including workshops examining a in this area by hosting roundtable discussions attended by a large number of interested stakeholders, methods, and the future of potential partnerships that will be or are being impacted by this announce- well as to identify bottlenecks in biomarker development and implementation, in clinical drug develop- broad range of topics such as: such as at the Society for Neuroscience annual meetings. ment. In addition to real-time datasets that are open to academics, industry, and other researchers, ment for schizophrenia. ⢠Sex differences and implications for translational neuroscience research participants identified partnering with the proper stakeholders as good first steps. A workshop summary International Laws Regarding the Use of Animals and the Neuroscience Grand Challenges in ⢠Glutamate-related biomarkers in schizophrenia drug development will be available in early 2010 through the Forumâs website. Research Enterprise Neuroscience ⢠Translational research for clinical neuroscience applications ⢠International animal law and the neuroscience research enterprise Neuroscience and Animals in Research The Forum, in conjunction with the National Research Councilâs Committee on Science, Technology, This working group continues to follow up on the efforts set out by the workshop We look forward to another productive and interesting year for the Forum. In November, the Forum brought together biomedical and veterinary research scientists, legal scholars and Law and the Institute for Laboratory Animal Research, will plan and host a workshop that will bring on grand challenges in neuroscience. and practitioners of law regarding the use of animals (âanimal lawâ), and ethicists to engage in meaningful together representatives from Europe and the United States to examine laws, directives, and policies The working group is helping to facili- dialogue about the emergence of animal law and practice and its relationship to the medical and life sci- designed to regulate the use of non-human animals in the medical research enterprise, including a tate a strategic plan for federal research ences research enterprise. This meeting was co-hosted with the National Research Councilâs Committee particular focus on the neurosciences. Specifically, participants will identify and discuss current animal and coordinationâengaging the com- on Science, Technology, and Law. Animal law is a fast-growing area of concentration for many students use regulations in Europe and the United States; examine the implications of current policies on the Alan Leshner munity in identifying and prioritizing Chair at leading American law schools. The debate over the legal and social status of non-human animals is research enterprise, including the impact of disparate policies; discuss developments in law school the opportunities, evaluating social and not restricted to just the United States, however, as several countries are re-examining the use of animals curricula, animal law practice, and activity in the courts that may affect the use of animals in research; ethical impacts, and determining the in research and some are deciding future restrictions for certain animals. The meeting sparked interest in explore the reasons for the establishment of specific regulations; and, discuss opportunities for harmo- resources that will be required. moving beyond United States borders and engaging in a dialogue with international stakeholders in order nization of regulations across jurisdictions. to understand the impact and future of animal use regulations in Europe and the United States. Mental Health Nurse, Budima Health Center, Jinja, Uganda, August 2009
MESSAGE REFLECTING BACK LO O K I N G A H E A D FROM THE CHAIR FORUM ACTIVITIES IN 2009 FORUM ACTIVITIES FOR 2010 Mental, Neurological, and Substance Use Disorders in sub-Saharan Africa Sex Differences and Implications for Translational Neuroscience Research T he Institute of Medicine (IOM) established the In August, the Forum, in collaboration with the Forum on Health and Nutrition of the Uganda National The Forum is hosting a workshop to explore the key principles and strategies used by basic transla- Forum on Neuroscience Academy of Sciences, convened an international workshop in Kampala, Uganda on quality of care tional researchers and industry in studying sex differences in the neurosciences for the therapy devel- and Nervous System issues for mental, neurological, and substance use disorders in sub-Saharan Africa. In light of the opment pathway. Speakers will outline the public health importance of studying sex difference in the Disorders to engage neu- economic limitation of most sub-Saharan African countries, the workshop set out to explore areas nervous system, in health and sickness, including the potential application to healthcare delivery. A CNS Clinical Trials: Suicidality and Data Collection workshop participants, June 2009 roscience leaders from private sector where policies might improve care, opportunities that could be used to better ensure continuity of care large emphasis will be on discussing the scientific principles that should be considered when design- sponsors of biomedical and clinical and sustainability within a countryâs health care system, and resources that are presently available or ing pre-clinical experiments that will examine sex differences, including strategies to bridge between research, federal agencies sponsor- could be made available to aid in implementation of treatments and prevention projects. Participants pre-clinical and clinical studies; when and how sex differences should and should not be considered; ing and regulating basic biomedical emphasized the need for more action, investment, and commitment by all stakeholders, national and and the key principles and strategies used by academic clinicians to effectively utilize basic research WORKING GROUPS and clinical research, private founda- international. The summary of the workshop will be released in Spring 2010 and will be found on the for pre-clinical and clinical application and study. tions, the academic community, and Working groups are established and maintained by interested members and are open to all member- Forumâs website (www.iom.edu/neuroforum). other consumers. Facilitating Translational Research for Clinical Neuroscience Applications ship. The Forumâs working groups engage in regular discussions, usually via teleconferences, on topics 2009 SfN Annual Meeting: Social Issues Roundtable Individuals from pharmaceutical and diagnostic industry, academia, and the National Institutes of of interest to that group. Workshop topics often originate from working groups and are organized by an Through its quarterly meetings and Alan Leshner The Forum organized the Social Issues Roundtable at the 2009 meeting of the Society for Neuroscience. Health will join members of the Forum in a meeting on translational research for clinical neuroscience independently appointed workshop planning committee. public workshops, the Forum has provided a venue where its members, The purpose of this discussion was to begin to engage neuroscientists in a dialogue about the ethical applications. The meeting will stimulate discussions aimed at improving the understanding between other leaders from the neurosciences, and members of the public can have Translational Neuroscience candid discussions about issues of mutual interest. We believe these discus- and social implications of research findings as the field continues to find the scientific underpinnings what pharmaceutical and diagnostic developers are looking for and how academic researchers can best The translational neuroscience working group was established to focus on identifying areas of synergy sions enhance understanding of research and clinical issues associated with of what âmakesâ us human. For example, new insights into the nature of the brain and mind can have contribute to the partnership in a meaningful way in order to improve the neuroscience translational where public and private sector stakeholders can partner to improve the efficiency and effectiveness of the nervous system among the scientific community and the general public, great implications for such concepts as the self, soul, free will, or what it means to be human. Speakers research pipeline. Discussions and presentations will also focus on how to bridge the interface between drug discovery and development for neurological and mental disorders. The group is currently develop- and provide a mechanism to foster partnerships among stakeholders. This was in the roundtable discussed both the nature of those issues, and ways the scientific community can best basic and drug/diagnostic development researchers in the neurosciences. ing a workshop aimed at improving the understanding between what pharmaceutical and diagnostic exemplified in 2009 when the Forum collaborated with the Uganda National engage the public, find common ground, and minimize the tension that could arise between the field Glutamate-related Biomarkers for Disorders of the Nervous System developers are looking for and how academic researchers can best contribute to the partnership in a Academy of Sciences to host an international workshop on mental, neurologi- and the rest of society. Identification of reliable biomarkers reflecting glutamatergic dysfunction may permit selection of meaningful way in order to improve the neuroscience translational research pipeline. cal, and substance use disorders. The workshop, a true collaboration across CNS Clinical Trials: Suicidality and Data Collection patients who will gain greater benefit from glutamate-directed treatments. Present medications, while continents, brought together a wide range of stakeholders to discuss important Social Issues in Neuroscience The Forum hosted a workshop in June in response to an emerging need to examine a recent Food and advanced over the initial compounds, nevertheless provide unsatisfactory treatment for individuals topics that we hope will move to the fore issues related to these disorders that A working group was established to engage neuroscientists in a dialogue about the critical time neuro- Drug Administration policy that requires all clinical protocols for products developed in the Division of with a range of central nervous system disorders with persistent negative symptoms, significant cogni- plague so many individuals in this region. science is entering with regard to ethical and social implications of research findings as the field con- Psychiatry Products of the FDA, whatever the indication, to include a prospective assessment for suicid- tive deficits, and poor function, characteristics associated with glutamatergic dysfunction by emerging The Forum undertook a broad set of initiatives in 2009 and, in 2010, the tinues to find the scientific underpinnings of what âmakesâ us human. The group is continuing efforts ality. Workshop participants examined and discussed the state of currently available data, data analysis evidence. The goal of the workshop is to gain an enhanced understanding of the role of biomarkers, as Forum plans to host a variety of activities, including workshops examining a in this area by hosting roundtable discussions attended by a large number of interested stakeholders, methods, and the future of potential partnerships that will be or are being impacted by this announce- well as to identify bottlenecks in biomarker development and implementation, in clinical drug develop- broad range of topics such as: such as at the Society for Neuroscience annual meetings. ment. In addition to real-time datasets that are open to academics, industry, and other researchers, ment for schizophrenia. ⢠Sex differences and implications for translational neuroscience research participants identified partnering with the proper stakeholders as good first steps. A workshop summary International Laws Regarding the Use of Animals and the Neuroscience Grand Challenges in ⢠Glutamate-related biomarkers in schizophrenia drug development will be available in early 2010 through the Forumâs website. Research Enterprise Neuroscience ⢠Translational research for clinical neuroscience applications ⢠International animal law and the neuroscience research enterprise Neuroscience and Animals in Research The Forum, in conjunction with the National Research Councilâs Committee on Science, Technology, This working group continues to follow up on the efforts set out by the workshop We look forward to another productive and interesting year for the Forum. In November, the Forum brought together biomedical and veterinary research scientists, legal scholars and Law and the Institute for Laboratory Animal Research, will plan and host a workshop that will bring on grand challenges in neuroscience. and practitioners of law regarding the use of animals (âanimal lawâ), and ethicists to engage in meaningful together representatives from Europe and the United States to examine laws, directives, and policies The working group is helping to facili- dialogue about the emergence of animal law and practice and its relationship to the medical and life sci- designed to regulate the use of non-human animals in the medical research enterprise, including a tate a strategic plan for federal research ences research enterprise. This meeting was co-hosted with the National Research Councilâs Committee particular focus on the neurosciences. Specifically, participants will identify and discuss current animal and coordinationâengaging the com- on Science, Technology, and Law. Animal law is a fast-growing area of concentration for many students use regulations in Europe and the United States; examine the implications of current policies on the Alan Leshner munity in identifying and prioritizing Chair at leading American law schools. The debate over the legal and social status of non-human animals is research enterprise, including the impact of disparate policies; discuss developments in law school the opportunities, evaluating social and not restricted to just the United States, however, as several countries are re-examining the use of animals curricula, animal law practice, and activity in the courts that may affect the use of animals in research; ethical impacts, and determining the in research and some are deciding future restrictions for certain animals. The meeting sparked interest in explore the reasons for the establishment of specific regulations; and, discuss opportunities for harmo- resources that will be required. moving beyond United States borders and engaging in a dialogue with international stakeholders in order nization of regulations across jurisdictions. to understand the impact and future of animal use regulations in Europe and the United States. Mental Health Nurse, Budima Health Center, Jinja, Uganda, August 2009
MESSAGE REFLECTING BACK LO O K I N G A H E A D FROM THE CHAIR FORUM ACTIVITIES IN 2009 FORUM ACTIVITIES FOR 2010 Mental, Neurological, and Substance Use Disorders in sub-Saharan Africa Sex Differences and Implications for Translational Neuroscience Research T he Institute of Medicine (IOM) established the In August, the Forum, in collaboration with the Forum on Health and Nutrition of the Uganda National The Forum is hosting a workshop to explore the key principles and strategies used by basic transla- Forum on Neuroscience Academy of Sciences, convened an international workshop in Kampala, Uganda on quality of care tional researchers and industry in studying sex differences in the neurosciences for the therapy devel- and Nervous System issues for mental, neurological, and substance use disorders in sub-Saharan Africa. In light of the opment pathway. Speakers will outline the public health importance of studying sex difference in the Disorders to engage neu- economic limitation of most sub-Saharan African countries, the workshop set out to explore areas nervous system, in health and sickness, including the potential application to healthcare delivery. A CNS Clinical Trials: Suicidality and Data Collection workshop participants, June 2009 roscience leaders from private sector where policies might improve care, opportunities that could be used to better ensure continuity of care large emphasis will be on discussing the scientific principles that should be considered when design- sponsors of biomedical and clinical and sustainability within a countryâs health care system, and resources that are presently available or ing pre-clinical experiments that will examine sex differences, including strategies to bridge between research, federal agencies sponsor- could be made available to aid in implementation of treatments and prevention projects. Participants pre-clinical and clinical studies; when and how sex differences should and should not be considered; ing and regulating basic biomedical emphasized the need for more action, investment, and commitment by all stakeholders, national and and the key principles and strategies used by academic clinicians to effectively utilize basic research WORKING GROUPS and clinical research, private founda- international. The summary of the workshop will be released in Spring 2010 and will be found on the for pre-clinical and clinical application and study. tions, the academic community, and Working groups are established and maintained by interested members and are open to all member- Forumâs website (www.iom.edu/neuroforum). other consumers. Facilitating Translational Research for Clinical Neuroscience Applications ship. The Forumâs working groups engage in regular discussions, usually via teleconferences, on topics 2009 SfN Annual Meeting: Social Issues Roundtable Individuals from pharmaceutical and diagnostic industry, academia, and the National Institutes of of interest to that group. Workshop topics often originate from working groups and are organized by an Through its quarterly meetings and Alan Leshner The Forum organized the Social Issues Roundtable at the 2009 meeting of the Society for Neuroscience. Health will join members of the Forum in a meeting on translational research for clinical neuroscience independently appointed workshop planning committee. public workshops, the Forum has provided a venue where its members, The purpose of this discussion was to begin to engage neuroscientists in a dialogue about the ethical applications. The meeting will stimulate discussions aimed at improving the understanding between other leaders from the neurosciences, and members of the public can have Translational Neuroscience candid discussions about issues of mutual interest. We believe these discus- and social implications of research findings as the field continues to find the scientific underpinnings what pharmaceutical and diagnostic developers are looking for and how academic researchers can best The translational neuroscience working group was established to focus on identifying areas of synergy sions enhance understanding of research and clinical issues associated with of what âmakesâ us human. For example, new insights into the nature of the brain and mind can have contribute to the partnership in a meaningful way in order to improve the neuroscience translational where public and private sector stakeholders can partner to improve the efficiency and effectiveness of the nervous system among the scientific community and the general public, great implications for such concepts as the self, soul, free will, or what it means to be human. Speakers research pipeline. Discussions and presentations will also focus on how to bridge the interface between drug discovery and development for neurological and mental disorders. The group is currently develop- and provide a mechanism to foster partnerships among stakeholders. This was in the roundtable discussed both the nature of those issues, and ways the scientific community can best basic and drug/diagnostic development researchers in the neurosciences. ing a workshop aimed at improving the understanding between what pharmaceutical and diagnostic exemplified in 2009 when the Forum collaborated with the Uganda National engage the public, find common ground, and minimize the tension that could arise between the field Glutamate-related Biomarkers for Disorders of the Nervous System developers are looking for and how academic researchers can best contribute to the partnership in a Academy of Sciences to host an international workshop on mental, neurologi- and the rest of society. Identification of reliable biomarkers reflecting glutamatergic dysfunction may permit selection of meaningful way in order to improve the neuroscience translational research pipeline. cal, and substance use disorders. The workshop, a true collaboration across CNS Clinical Trials: Suicidality and Data Collection patients who will gain greater benefit from glutamate-directed treatments. Present medications, while continents, brought together a wide range of stakeholders to discuss important Social Issues in Neuroscience The Forum hosted a workshop in June in response to an emerging need to examine a recent Food and advanced over the initial compounds, nevertheless provide unsatisfactory treatment for individuals topics that we hope will move to the fore issues related to these disorders that A working group was established to engage neuroscientists in a dialogue about the critical time neuro- Drug Administration policy that requires all clinical protocols for products developed in the Division of with a range of central nervous system disorders with persistent negative symptoms, significant cogni- plague so many individuals in this region. science is entering with regard to ethical and social implications of research findings as the field con- Psychiatry Products of the FDA, whatever the indication, to include a prospective assessment for suicid- tive deficits, and poor function, characteristics associated with glutamatergic dysfunction by emerging The Forum undertook a broad set of initiatives in 2009 and, in 2010, the tinues to find the scientific underpinnings of what âmakesâ us human. The group is continuing efforts ality. Workshop participants examined and discussed the state of currently available data, data analysis evidence. The goal of the workshop is to gain an enhanced understanding of the role of biomarkers, as Forum plans to host a variety of activities, including workshops examining a in this area by hosting roundtable discussions attended by a large number of interested stakeholders, methods, and the future of potential partnerships that will be or are being impacted by this announce- well as to identify bottlenecks in biomarker development and implementation, in clinical drug develop- broad range of topics such as: such as at the Society for Neuroscience annual meetings. ment. In addition to real-time datasets that are open to academics, industry, and other researchers, ment for schizophrenia. ⢠Sex differences and implications for translational neuroscience research participants identified partnering with the proper stakeholders as good first steps. A workshop summary International Laws Regarding the Use of Animals and the Neuroscience Grand Challenges in ⢠Glutamate-related biomarkers in schizophrenia drug development will be available in early 2010 through the Forumâs website. Research Enterprise Neuroscience ⢠Translational research for clinical neuroscience applications ⢠International animal law and the neuroscience research enterprise Neuroscience and Animals in Research The Forum, in conjunction with the National Research Councilâs Committee on Science, Technology, This working group continues to follow up on the efforts set out by the workshop We look forward to another productive and interesting year for the Forum. In November, the Forum brought together biomedical and veterinary research scientists, legal scholars and Law and the Institute for Laboratory Animal Research, will plan and host a workshop that will bring on grand challenges in neuroscience. and practitioners of law regarding the use of animals (âanimal lawâ), and ethicists to engage in meaningful together representatives from Europe and the United States to examine laws, directives, and policies The working group is helping to facili- dialogue about the emergence of animal law and practice and its relationship to the medical and life sci- designed to regulate the use of non-human animals in the medical research enterprise, including a tate a strategic plan for federal research ences research enterprise. This meeting was co-hosted with the National Research Councilâs Committee particular focus on the neurosciences. Specifically, participants will identify and discuss current animal and coordinationâengaging the com- on Science, Technology, and Law. Animal law is a fast-growing area of concentration for many students use regulations in Europe and the United States; examine the implications of current policies on the Alan Leshner munity in identifying and prioritizing Chair at leading American law schools. The debate over the legal and social status of non-human animals is research enterprise, including the impact of disparate policies; discuss developments in law school the opportunities, evaluating social and not restricted to just the United States, however, as several countries are re-examining the use of animals curricula, animal law practice, and activity in the courts that may affect the use of animals in research; ethical impacts, and determining the in research and some are deciding future restrictions for certain animals. The meeting sparked interest in explore the reasons for the establishment of specific regulations; and, discuss opportunities for harmo- resources that will be required. moving beyond United States borders and engaging in a dialogue with international stakeholders in order nization of regulations across jurisdictions. to understand the impact and future of animal use regulations in Europe and the United States. Mental Health Nurse, Budima Health Center, Jinja, Uganda, August 2009
MESSAGE REFLECTING BACK LO O K I N G A H E A D FROM THE CHAIR FORUM ACTIVITIES IN 2009 FORUM ACTIVITIES FOR 2010 Mental, Neurological, and Substance Use Disorders in sub-Saharan Africa Sex Differences and Implications for Translational Neuroscience Research T he Institute of Medicine (IOM) established the In August, the Forum, in collaboration with the Forum on Health and Nutrition of the Uganda National The Forum is hosting a workshop to explore the key principles and strategies used by basic transla- Forum on Neuroscience Academy of Sciences, convened an international workshop in Kampala, Uganda on quality of care tional researchers and industry in studying sex differences in the neurosciences for the therapy devel- and Nervous System issues for mental, neurological, and substance use disorders in sub-Saharan Africa. In light of the opment pathway. Speakers will outline the public health importance of studying sex difference in the Disorders to engage neu- economic limitation of most sub-Saharan African countries, the workshop set out to explore areas nervous system, in health and sickness, including the potential application to healthcare delivery. A CNS Clinical Trials: Suicidality and Data Collection workshop participants, June 2009 roscience leaders from private sector where policies might improve care, opportunities that could be used to better ensure continuity of care large emphasis will be on discussing the scientific principles that should be considered when design- sponsors of biomedical and clinical and sustainability within a countryâs health care system, and resources that are presently available or ing pre-clinical experiments that will examine sex differences, including strategies to bridge between research, federal agencies sponsor- could be made available to aid in implementation of treatments and prevention projects. Participants pre-clinical and clinical studies; when and how sex differences should and should not be considered; ing and regulating basic biomedical emphasized the need for more action, investment, and commitment by all stakeholders, national and and the key principles and strategies used by academic clinicians to effectively utilize basic research WORKING GROUPS and clinical research, private founda- international. The summary of the workshop will be released in Spring 2010 and will be found on the for pre-clinical and clinical application and study. tions, the academic community, and Working groups are established and maintained by interested members and are open to all member- Forumâs website (www.iom.edu/neuroforum). other consumers. Facilitating Translational Research for Clinical Neuroscience Applications ship. The Forumâs working groups engage in regular discussions, usually via teleconferences, on topics 2009 SfN Annual Meeting: Social Issues Roundtable Individuals from pharmaceutical and diagnostic industry, academia, and the National Institutes of of interest to that group. Workshop topics often originate from working groups and are organized by an Through its quarterly meetings and Alan Leshner The Forum organized the Social Issues Roundtable at the 2009 meeting of the Society for Neuroscience. Health will join members of the Forum in a meeting on translational research for clinical neuroscience independently appointed workshop planning committee. public workshops, the Forum has provided a venue where its members, The purpose of this discussion was to begin to engage neuroscientists in a dialogue about the ethical applications. The meeting will stimulate discussions aimed at improving the understanding between other leaders from the neurosciences, and members of the public can have Translational Neuroscience candid discussions about issues of mutual interest. We believe these discus- and social implications of research findings as the field continues to find the scientific underpinnings what pharmaceutical and diagnostic developers are looking for and how academic researchers can best The translational neuroscience working group was established to focus on identifying areas of synergy sions enhance understanding of research and clinical issues associated with of what âmakesâ us human. For example, new insights into the nature of the brain and mind can have contribute to the partnership in a meaningful way in order to improve the neuroscience translational where public and private sector stakeholders can partner to improve the efficiency and effectiveness of the nervous system among the scientific community and the general public, great implications for such concepts as the self, soul, free will, or what it means to be human. Speakers research pipeline. Discussions and presentations will also focus on how to bridge the interface between drug discovery and development for neurological and mental disorders. The group is currently develop- and provide a mechanism to foster partnerships among stakeholders. This was in the roundtable discussed both the nature of those issues, and ways the scientific community can best basic and drug/diagnostic development researchers in the neurosciences. ing a workshop aimed at improving the understanding between what pharmaceutical and diagnostic exemplified in 2009 when the Forum collaborated with the Uganda National engage the public, find common ground, and minimize the tension that could arise between the field Glutamate-related Biomarkers for Disorders of the Nervous System developers are looking for and how academic researchers can best contribute to the partnership in a Academy of Sciences to host an international workshop on mental, neurologi- and the rest of society. Identification of reliable biomarkers reflecting glutamatergic dysfunction may permit selection of meaningful way in order to improve the neuroscience translational research pipeline. cal, and substance use disorders. The workshop, a true collaboration across CNS Clinical Trials: Suicidality and Data Collection patients who will gain greater benefit from glutamate-directed treatments. Present medications, while continents, brought together a wide range of stakeholders to discuss important Social Issues in Neuroscience The Forum hosted a workshop in June in response to an emerging need to examine a recent Food and advanced over the initial compounds, nevertheless provide unsatisfactory treatment for individuals topics that we hope will move to the fore issues related to these disorders that A working group was established to engage neuroscientists in a dialogue about the critical time neuro- Drug Administration policy that requires all clinical protocols for products developed in the Division of with a range of central nervous system disorders with persistent negative symptoms, significant cogni- plague so many individuals in this region. science is entering with regard to ethical and social implications of research findings as the field con- Psychiatry Products of the FDA, whatever the indication, to include a prospective assessment for suicid- tive deficits, and poor function, characteristics associated with glutamatergic dysfunction by emerging The Forum undertook a broad set of initiatives in 2009 and, in 2010, the tinues to find the scientific underpinnings of what âmakesâ us human. The group is continuing efforts ality. Workshop participants examined and discussed the state of currently available data, data analysis evidence. The goal of the workshop is to gain an enhanced understanding of the role of biomarkers, as Forum plans to host a variety of activities, including workshops examining a in this area by hosting roundtable discussions attended by a large number of interested stakeholders, methods, and the future of potential partnerships that will be or are being impacted by this announce- well as to identify bottlenecks in biomarker development and implementation, in clinical drug develop- broad range of topics such as: such as at the Society for Neuroscience annual meetings. ment. In addition to real-time datasets that are open to academics, industry, and other researchers, ment for schizophrenia. ⢠Sex differences and implications for translational neuroscience research participants identified partnering with the proper stakeholders as good first steps. A workshop summary International Laws Regarding the Use of Animals and the Neuroscience Grand Challenges in ⢠Glutamate-related biomarkers in schizophrenia drug development will be available in early 2010 through the Forumâs website. Research Enterprise Neuroscience ⢠Translational research for clinical neuroscience applications ⢠International animal law and the neuroscience research enterprise Neuroscience and Animals in Research The Forum, in conjunction with the National Research Councilâs Committee on Science, Technology, This working group continues to follow up on the efforts set out by the workshop We look forward to another productive and interesting year for the Forum. In November, the Forum brought together biomedical and veterinary research scientists, legal scholars and Law and the Institute for Laboratory Animal Research, will plan and host a workshop that will bring on grand challenges in neuroscience. and practitioners of law regarding the use of animals (âanimal lawâ), and ethicists to engage in meaningful together representatives from Europe and the United States to examine laws, directives, and policies The working group is helping to facili- dialogue about the emergence of animal law and practice and its relationship to the medical and life sci- designed to regulate the use of non-human animals in the medical research enterprise, including a tate a strategic plan for federal research ences research enterprise. This meeting was co-hosted with the National Research Councilâs Committee particular focus on the neurosciences. Specifically, participants will identify and discuss current animal and coordinationâengaging the com- on Science, Technology, and Law. Animal law is a fast-growing area of concentration for many students use regulations in Europe and the United States; examine the implications of current policies on the Alan Leshner munity in identifying and prioritizing Chair at leading American law schools. The debate over the legal and social status of non-human animals is research enterprise, including the impact of disparate policies; discuss developments in law school the opportunities, evaluating social and not restricted to just the United States, however, as several countries are re-examining the use of animals curricula, animal law practice, and activity in the courts that may affect the use of animals in research; ethical impacts, and determining the in research and some are deciding future restrictions for certain animals. The meeting sparked interest in explore the reasons for the establishment of specific regulations; and, discuss opportunities for harmo- resources that will be required. moving beyond United States borders and engaging in a dialogue with international stakeholders in order nization of regulations across jurisdictions. to understand the impact and future of animal use regulations in Europe and the United States. Mental Health Nurse, Budima Health Center, Jinja, Uganda, August 2009
About the Neuroscience Forum FORUM MEMBERSHIP The IOM in 2006 established the Forum on Neuroscience and Nervous (AS OF DECEMBER 2009) System Disorders. The Forum is designed to provide its members with a venue for exchanging information, sharing individual views, and allowing a structured opportunity for dialogue and discussion while scrutinizing critical Alan Leshner (Chair) Husseini Manji and possibly contentious scientific and policy issues. Representatives from American Association for the Advancement Johnson & Johnson Pharmaceuticals government, industry, academia, patient advocacy organizations, and other interested parties serve as Forum members. It convenes three times a year to of Science Eve Marder 2009 ANNUAL REPORT Huda Akil Brandeis University confer on subject areas of mutual interest and concern. At its meetings, the University of Michigan, Ann Arbor Forum identifies and discusses emerging scientific and policy issues related to Jonathan Moreno basic neuroscience and nervous system disorders, as well as effective clinical Marc Barlow University of Pennsylvania interventions and policy options. The Forum also sponsors workshops (sympo- GE Healthcare Steve Hyman welcomes participants to the workshop on Mental, Neurological, and Substance Use Disorders in sub-Saharan Africa, August 2009 Michael Oberdorfer sia) as an additional mechanism for informing the membership of the Forum, Mark Bear National Eye Institute, NIH Neuroscience other relevant stakeholders, and the public. Information about past or upcom- Massachusetts Institute of Technology Blueprint representative ing meetings is available at the Forumâs website, www.iom.edu/neuroforum. Daniel Burch Kathie Olsen FORUM SPONSORSHIP About the Institute of Medicine The Institute of Medicine serves as adviser to the nation to improve health. CeNeRx Biopharma Dennis Choi National Science Foundation Atul Pande Financial support for the Forum is derived from federal agencies, patient advocacy organizations, industry, and a non-profit membership society. FORUM ON Established in 1970 under the charter of the National Academy of Sciences, Emory University GlaxoSmithKline the Institute of Medicine provides independent, objective, evidence-based Alzheimerâs Association National Institute on Alcohol Abuse and advice to policymakers, health professionals, the private sector, and the pub- lic. The mission of the Institute of Medicine embraces the health of people Timothy Coetzee FastForward of the National Multiple Sclerosis Society Menelas Pangalos Wyeth Research AstraZeneca Pharmaceuticals CeNeRx Biopharma Alcoholism National Institute on Drug Abuse NEUROSCIENCE everywhere. Steven Paul Eli Lilly and Company National Institutes of Health Neuroscience David Cohen Eli Lilly and Company GE Healthcare Blueprint IOM Staff Columbia University, Society for Neuroscience representative William Potter GlaxoSmithKline Johnson & Johnson Pharmaceuticals National Institute of Mental Health National Institute of Neurological Disorders AND Merck Research Laboratories Bruce Altevogt, Ph.D. Lundbeck Research USA, Inc. and Stroke Richard Frank Project Director Paul Sieving NERVOUS SYSTEM Merck Research Laboratories National Multiple Sclerosis Society GE Healthcare Sarah Hanson National Eye Institute The Michael J. Fox Foundation for National Science Foundation Associate Program Officer John Griffin Parkinsonâs Research Society for Neuroscience Rae Silver Johns Hopkins University National Eye Institute Wyeth Research Lora Taylor Columbia University DISORDERS Senior Project Assistant Richard Hodes National Institute on Aging William Thies National Institute on Aging IOM Board on Health Sciences Policy Alzheimerâs Association Katie Hood Neuroscience Forum Funding: 2009 Andrew M. Pope, Ph.D. Nora Volkow Director The Michael J. Fox Foundation for National Institute on Drug Abuse Nonprofit Industry Federal Parkinsonâs Research Kenneth Warren Steven Hyman National Institute on Alcohol Abuse and 19% Harvard University Alcoholism Thomas Insel Frank Yocca National Institute of Mental Health AstraZeneca Pharmaceuticals 38% BOARD ON Story Landis Stevin Zorn HEALTH National Institute of Neurological Disorders Lundbeck Research USA, Inc. SCIENCES and Stroke For additional information on the Forum on Neuroscience and Nervous System Charles Zorumski 43% POLICY Disorders visit the Forumâs website at www.iom.edu/neuroforum, Washington University, St. Louis or call Bruce Altevogt at (202) 334-3984.
About the Neuroscience Forum FORUM MEMBERSHIP The IOM in 2006 established the Forum on Neuroscience and Nervous (AS OF DECEMBER 2009) System Disorders. The Forum is designed to provide its members with a venue for exchanging information, sharing individual views, and allowing a structured opportunity for dialogue and discussion while scrutinizing critical Alan Leshner (Chair) Husseini Manji and possibly contentious scientific and policy issues. Representatives from American Association for the Advancement Johnson & Johnson Pharmaceuticals government, industry, academia, patient advocacy organizations, and other interested parties serve as Forum members. It convenes three times a year to of Science Eve Marder 2009 ANNUAL REPORT Huda Akil Brandeis University confer on subject areas of mutual interest and concern. At its meetings, the University of Michigan, Ann Arbor Forum identifies and discusses emerging scientific and policy issues related to Jonathan Moreno basic neuroscience and nervous system disorders, as well as effective clinical Marc Barlow University of Pennsylvania interventions and policy options. The Forum also sponsors workshops (sympo- GE Healthcare Steve Hyman welcomes participants to the workshop on Mental, Neurological, and Substance Use Disorders in sub-Saharan Africa, August 2009 Michael Oberdorfer sia) as an additional mechanism for informing the membership of the Forum, Mark Bear National Eye Institute, NIH Neuroscience other relevant stakeholders, and the public. Information about past or upcom- Massachusetts Institute of Technology Blueprint representative ing meetings is available at the Forumâs website, www.iom.edu/neuroforum. Daniel Burch Kathie Olsen FORUM SPONSORSHIP About the Institute of Medicine The Institute of Medicine serves as adviser to the nation to improve health. CeNeRx Biopharma Dennis Choi National Science Foundation Atul Pande Financial support for the Forum is derived from federal agencies, patient advocacy organizations, industry, and a non-profit membership society. FORUM ON Established in 1970 under the charter of the National Academy of Sciences, Emory University GlaxoSmithKline the Institute of Medicine provides independent, objective, evidence-based Alzheimerâs Association National Institute on Alcohol Abuse and advice to policymakers, health professionals, the private sector, and the pub- lic. The mission of the Institute of Medicine embraces the health of people Timothy Coetzee FastForward of the National Multiple Sclerosis Society Menelas Pangalos Wyeth Research AstraZeneca Pharmaceuticals CeNeRx Biopharma Alcoholism National Institute on Drug Abuse NEUROSCIENCE everywhere. Steven Paul Eli Lilly and Company National Institutes of Health Neuroscience David Cohen Eli Lilly and Company GE Healthcare Blueprint IOM Staff Columbia University, Society for Neuroscience representative William Potter GlaxoSmithKline Johnson & Johnson Pharmaceuticals National Institute of Mental Health National Institute of Neurological Disorders AND Merck Research Laboratories Bruce Altevogt, Ph.D. Lundbeck Research USA, Inc. and Stroke Richard Frank Project Director Paul Sieving NERVOUS SYSTEM Merck Research Laboratories National Multiple Sclerosis Society GE Healthcare Sarah Hanson National Eye Institute The Michael J. Fox Foundation for National Science Foundation Associate Program Officer John Griffin Parkinsonâs Research Society for Neuroscience Rae Silver Johns Hopkins University National Eye Institute Wyeth Research Lora Taylor Columbia University DISORDERS Senior Project Assistant Richard Hodes National Institute on Aging William Thies National Institute on Aging IOM Board on Health Sciences Policy Alzheimerâs Association Katie Hood Neuroscience Forum Funding: 2009 Andrew M. Pope, Ph.D. Nora Volkow Director The Michael J. Fox Foundation for National Institute on Drug Abuse Nonprofit Industry Federal Parkinsonâs Research Kenneth Warren Steven Hyman National Institute on Alcohol Abuse and 19% Harvard University Alcoholism Thomas Insel Frank Yocca National Institute of Mental Health AstraZeneca Pharmaceuticals 38% BOARD ON Story Landis Stevin Zorn HEALTH National Institute of Neurological Disorders Lundbeck Research USA, Inc. SCIENCES and Stroke For additional information on the Forum on Neuroscience and Nervous System Charles Zorumski 43% POLICY Disorders visit the Forumâs website at www.iom.edu/neuroforum, Washington University, St. Louis or call Bruce Altevogt at (202) 334-3984.
About the Neuroscience Forum FORUM MEMBERSHIP The IOM in 2006 established the Forum on Neuroscience and Nervous (AS OF DECEMBER 2009) System Disorders. The Forum is designed to provide its members with a venue for exchanging information, sharing individual views, and allowing a structured opportunity for dialogue and discussion while scrutinizing critical Alan Leshner (Chair) Husseini Manji and possibly contentious scientific and policy issues. Representatives from American Association for the Advancement Johnson & Johnson Pharmaceuticals government, industry, academia, patient advocacy organizations, and other interested parties serve as Forum members. It convenes three times a year to of Science Eve Marder 2009 ANNUAL REPORT Huda Akil Brandeis University confer on subject areas of mutual interest and concern. At its meetings, the University of Michigan, Ann Arbor Forum identifies and discusses emerging scientific and policy issues related to Jonathan Moreno basic neuroscience and nervous system disorders, as well as effective clinical Marc Barlow University of Pennsylvania interventions and policy options. The Forum also sponsors workshops (sympo- GE Healthcare Steve Hyman welcomes participants to the workshop on Mental, Neurological, and Substance Use Disorders in sub-Saharan Africa, August 2009 Michael Oberdorfer sia) as an additional mechanism for informing the membership of the Forum, Mark Bear National Eye Institute, NIH Neuroscience other relevant stakeholders, and the public. Information about past or upcom- Massachusetts Institute of Technology Blueprint representative ing meetings is available at the Forumâs website, www.iom.edu/neuroforum. Daniel Burch Kathie Olsen FORUM SPONSORSHIP About the Institute of Medicine The Institute of Medicine serves as adviser to the nation to improve health. CeNeRx Biopharma Dennis Choi National Science Foundation Atul Pande Financial support for the Forum is derived from federal agencies, patient advocacy organizations, industry, and a non-profit membership society. FORUM ON Established in 1970 under the charter of the National Academy of Sciences, Emory University GlaxoSmithKline the Institute of Medicine provides independent, objective, evidence-based Alzheimerâs Association National Institute on Alcohol Abuse and advice to policymakers, health professionals, the private sector, and the pub- lic. The mission of the Institute of Medicine embraces the health of people Timothy Coetzee FastForward of the National Multiple Sclerosis Society Menelas Pangalos Wyeth Research AstraZeneca Pharmaceuticals CeNeRx Biopharma Alcoholism National Institute on Drug Abuse NEUROSCIENCE everywhere. Steven Paul Eli Lilly and Company National Institutes of Health Neuroscience David Cohen Eli Lilly and Company GE Healthcare Blueprint IOM Staff Columbia University, Society for Neuroscience representative William Potter GlaxoSmithKline Johnson & Johnson Pharmaceuticals National Institute of Mental Health National Institute of Neurological Disorders AND Merck Research Laboratories Bruce Altevogt, Ph.D. Lundbeck Research USA, Inc. and Stroke Richard Frank Project Director Paul Sieving NERVOUS SYSTEM Merck Research Laboratories National Multiple Sclerosis Society GE Healthcare Sarah Hanson National Eye Institute The Michael J. Fox Foundation for National Science Foundation Associate Program Officer John Griffin Parkinsonâs Research Society for Neuroscience Rae Silver Johns Hopkins University National Eye Institute Wyeth Research Lora Taylor Columbia University DISORDERS Senior Project Assistant Richard Hodes National Institute on Aging William Thies National Institute on Aging IOM Board on Health Sciences Policy Alzheimerâs Association Katie Hood Neuroscience Forum Funding: 2009 Andrew M. Pope, Ph.D. Nora Volkow Director The Michael J. Fox Foundation for National Institute on Drug Abuse Nonprofit Industry Federal Parkinsonâs Research Kenneth Warren Steven Hyman National Institute on Alcohol Abuse and 19% Harvard University Alcoholism Thomas Insel Frank Yocca National Institute of Mental Health AstraZeneca Pharmaceuticals 38% BOARD ON Story Landis Stevin Zorn HEALTH National Institute of Neurological Disorders Lundbeck Research USA, Inc. SCIENCES and Stroke For additional information on the Forum on Neuroscience and Nervous System Charles Zorumski 43% POLICY Disorders visit the Forumâs website at www.iom.edu/neuroforum, Washington University, St. Louis or call Bruce Altevogt at (202) 334-3984.
